

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.

<http://hdl.handle.net/2066/29893>

Please be advised that this information was generated on 2019-02-15 and may be subject to change.

4. Gerstein HC, Mann JF, Yi Q *et al.* Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. *JAMA* 2001; 286: 421–426
5. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med* 2004; 351: 1296–1305
6. Hillege HL, Fidler V, Diercks GF *et al.* Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. *Circulation* 2002; 106: 1777–1782
7. Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. *Hypertension* 2000; 35: 898–903
8. Chen J, Muntner P, Hamm LL *et al.* The metabolic syndrome and chronic kidney disease in US adults. *Ann Intern Med* 2004; 140: 167–174
9. Jones CA, Francis ME, Eberhardt MS *et al.* Microalbuminuria in the US population: Third National Health and Nutrition Examination Survey. *Am J Kidney Dis* 2002; 39: 445–459
10. Palaniappan L, Carnethon M, Fortmann SP. Association between microalbuminuria and the metabolic syndrome: NHANES III. *Am J Hypertens* 2003; 16: 952–958
11. Clausen P, Jensen JS, Jensen G, Borch-Johnsen K, Feldt-Rasmussen B. Elevated urinary albumin excretion is associated with impaired arterial dilatatory capacity in clinically healthy subjects. *Circulation* 2001; 103: 1869–1874
12. Tuttle KR, Puhlman ME, Cooney SK, Short RA. Urinary albumin and insulin as predictors of coronary artery disease: an angiographic study. *Am J Kidney Dis* 1999; 34: 918–925
13. Hoehner CM, Greenlund KJ, Rith-Najarian S, Casper ML, McClellan WM. Association of the insulin resistance syndrome and microalbuminuria among nondiabetic native Americans. The Inter-Tribal Heart Project. *J Am Soc Nephrol* 2002; 13: 1626–1634
14. Hoy WE, Mathews JD, McCredie DA *et al.* The multidimensional nature of renal disease: rates and associations of albuminuria in an Australian Aboriginal community. *Kidney Int* 1998; 54: 1296–1304
15. Meigs JB, D'Agostino RB, Sr, Nathan DM, Rifai N, Wilson PW; Framingham Offspring Study. Longitudinal association of glycemia and microalbuminuria: the Framingham Offspring Study. *Diabetes Care* 2002; 25: 977–983
16. Segura J, Campo C, Roldan C *et al.* Hypertensive renal damage in metabolic syndrome is associated with glucose metabolism disturbances. *J Am Soc Nephrol* 2004; 15: S37–S42
17. Salmenniemi U, Ruotsalainen E, Pihlajamäki J *et al.* Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. *Circulation* 2004; 110: 3842–3848
18. Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD. Obesity-related glomerulopathy: an emerging epidemic. *Kidney Int* 2001; 59: 1498–1509
19. Adelman RD, Restaino IG, Alon US, Blowey DL. Proteinuria and focal segmental glomerulosclerosis in severely obese adolescents. *J Pediatr* 2001; 138: 481–485
20. Cohen AH. Massive obesity and the kidney. A morphologic and statistical study. *Am J Pathol* 1975; 81: 117–130
21. Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafter U. Glomerular hemodynamics in severe obesity. *Am J Physiol Renal Physiol* 2000; 278: F817–F822
22. Chagnac A, Weinstein T, Herman M, Hirsh J, Gafter U, Yaacov O. The effects of weight loss on renal function in patients with severe obesity. *J Am Soc Nephrol* 2003; 14: 1480–1486
23. Tuttle KR, Bruton JL. Effect of insulin therapy on renal hemodynamic response to amino acids and renal hypertrophy in non-insulin dependent diabetes. *Kidney Int* 1992; 42: 167–173
24. Tuttle KR, Bruton JL, Perusek M, Lancaster JL, Kopp DT, DeFronzo RA. Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus. *N Engl J Med* 1991; 324: 1626–1632
25. Tuttle KR, Puhlman ME, Cooney SK, Short RA. Effects of amino acids and glucagon on renal hemodynamics in type 1 diabetes. *Am J Physiol* 2002; 282: F103–F112
26. Kasiske BL, O'Donnell MP, Keane WF. The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. *Hypertension* 1992; 19: I110–I115
27. Chua SC, White DW, Wu-Peng S *et al.* Phenotype of *fatty* due to Gln269Pro mutation in the leptin receptor (*Lepr*). *Diabetes* 1996; 45: 1141–1143
28. Maddox DA, Alavi FK, Santella RN, Zawada ET, Jr. Prevention of obesity-linked renal disease: age-dependent effects of dietary food restriction. *Kidney Int* 2002; 62: 208–219
29. Meek RL, Cooney SK, Flynn SD *et al.* Amino acids induce indicators of response to injury in glomerular mesangial cells. *Am J Physiol* 2003; 285: F79–F86
30. Tuttle KR, Johnson EC, Cooney SK *et al.* Amino acids injure mesangial cells by advanced glycation end products, oxidative stress, and protein kinase C. *Kidney Int* 2005 (in press)

Nephrol Dial Transplant (2005) 20: 864–867

doi:10.1093/ndt/gfh587

Advance Access publication 15 March 2005

Is vitamin D indispensable for Ca²⁺ homeostasis: lessons from knockout mouse models?

Joost G. J. Hoenderop and René J. M. Bindels

Department of Physiology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, The Netherlands

Correspondence and offprint requests to: René J. M. Bindels, 160 Physiology, Radboud University Nijmegen Medical Centre, PO Box 9101, NL-6500 HB Nijmegen, The Netherlands.
Email: R.Bindels@ncmls.ru.nl

Keywords: calcium diet; calcium reabsorption; 25-hydroxyvitamin D₃-1 α -hydroxylase; microarray; TRPV5

Role of vitamin D in the maintenance of Ca²⁺ balance

Calcium (Ca²⁺) is undoubtedly one of the most tightly regulated ions in plasma of higher animals. Ca²⁺ is involved in the normal functioning of a wide variety of tissues and physiological processes which include bone formation, muscle contraction, blood clotting, nerve transmission and as a second messenger regulating the actions of many hormones. The homeostasis of Ca²⁺ is complex because the gastrointestinal tract, the bones and the kidneys all affect the Ca²⁺ balance. Furthermore, the vitamin D endocrine system is critical for the proper development and maintenance of this Ca²⁺ homeostatic system. Once vitamin D is absorbed from the diet or made in the skin by the action of sunlight, it is metabolized in the liver to 25-hydroxyvitamin D and then the kidney serves as the endocrine gland to produce the biologically active form of vitamin D. This active form of vitamin D, 1 α ,25-dihydroxyvitamin D₃ [1,25(OH)₂D₃], is synthesized in the proximal tubule by the renal cytochrome P450 enzyme 25-hydroxyvitamin D₃-1 α -hydroxylase (1 α -OHase) [1]. The importance of this enzyme is underlined by severe disorders in Ca²⁺ homeostasis caused by mutations in the 1 α -OHase gene, including vitamin D-dependent rickets type I (VDDR-I). 1,25(OH)₂D₃ remains the most potent active form of vitamin D known to date. The intestine and kidney are the main target organs for the action of this hormone. The biological effects of 1,25(OH)₂D₃ on these target organs are mediated by both genomic and rapid post-transcriptional mechanisms [1]. 1 α ,25(OH)₂D₃ transcriptionally controls the expression of a particular set of target genes mediated through a nuclear vitamin D receptor (VDR) acting as a ligand-inducible factor. Upon binding 1,25(OH)₂D₃, the VDR undergoes a conformational change and forms a complex with a retinoid X receptor (RXR). This VDR–RXR complex binds to DNA elements in the promoter regions of target genes described as vitamin D response elements (VDREs). Binding to these VDREs controls the rate of gene transcription. The rapid response presumably utilizes another signal transduction pathway that is probably linked to putative plasma membrane receptors for 1,25(OH)₂D₃, but its physiological role is not well understood.

Vitamin D-deficient knockout mice models

Targeted deletion of genes encoding 1 α -OHase [2,3] and of the nuclear VDR [4,5] have provided useful mice models of inherited human diseases such as VDDR-I

(also known as pseudovitamin D-deficiency rickets; PDDR) and VDDR-II. Mice in which the 1 α -OHase gene was inactivated presented the same clinical phenotype as patients with PDDR, including undetectable levels of 1,25(OH)₂D₃, rickets and secondary hyperparathyroidism [2,3]. On a normal diet, 1 α -OHase knockout mice have an average life span of 12 \pm 2 weeks [3,6]. Previous studies indicated that daily injections of 1,25(OH)₂D₃ completely rescued these 1 α -OHase knockout mice [7]. Bone histology and histomorphometry confirmed that the rickets and osteomalacia were cured by this 1,25(OH)₂D₃ supplementation. Blood biochemistry analysis revealed that the rescue treatment corrected the hypocalcaemia and secondary hyperparathyroidism. Interestingly, these 1 α -OHase knockout mice were also rescued by a Ca enriched diet (2% w/w) [8]. Dietary Ca normalized the hypocalcaemia, secondary hyperparathyroidism and the biomechanical properties of the bone tissue. Comparable results were obtained in VDR knockout mice from which the bone phenotype could be completely rescued by feeding the animals an enriched Ca²⁺, phosphorus and lactose diet, suggesting that vitamin D deficiencies can be rescued by dietary Ca in a vitamin D-independent manner [4]. Other studies have however indicated that exogenous Ca may not entirely compensate for 1,25(OH)₂D₃ deficiency in mice and piglets [9,10]. In humans, beneficial effects of Ca infusions were reported in a child with hereditary resistance to 1,25(OH)₂D₃ and alopecia [11]. Ca infusions may be an efficient alternative for the management of patients with this condition who are unresponsive to large doses of vitamin D derivatives. However, it is not completely clear whether dietary Ca is effective in humans, and studies are needed in which vitamin D-deficient subjects are treated with Ca enriched diets.

Gene products involved in high dietary Ca rescue of 1 α -OHase knockout mice

The kidney has a predominant role in maintaining the Ca²⁺ balance because it determines the final excretion of Ca²⁺ in the urine. Active Ca²⁺ reabsorption in the distal convoluted and connecting tubule comprises a sequence of processes involving apical Ca²⁺ entry via transient receptor potential channel V5 (TRPV5), translocation of Ca²⁺ through the cytosol by calbindins and extrusion over the basolateral membrane by the Na⁺/Ca²⁺ exchanger (NCX1) and plasma membrane Ca²⁺ ATPase (PMCA1b) [12] (Figure 1). Recently, it was demonstrated that the expression of these renal Ca²⁺ transport proteins, with the exception of PMCA1b, is significantly downregulated in kidneys of 1 α -OHase knockout mice, which is in line with a diminished Ca²⁺ reabsorption capacity contributing to the development of the observed hypocalcaemia [6]. Intriguingly, high dietary Ca intake restored the decreased expression of the Ca²⁺ transport proteins independently from 1,25(OH)₂D₃ [6]. In order to




Fig. 1. Cellular model of renal epithelial Ca^{2+} transport. Active and transcellular Ca^{2+} transport is carried out as a three-step process. Following entry of Ca^{2+} through the epithelial Ca^{2+} channels, TRPV5 and TRPV6, Ca^{2+} bound to calbindin diffuses to the basolateral membrane. At the basolateral membrane, Ca^{2+} is extruded via an ATP-dependent Ca^{2+} -ATPase (PMCA1b) and a Na^{+} - Ca^{2+} exchanger (NCX1). In this way, there is net Ca^{2+} absorption from the luminal space to the extracellular compartment. Dietary Ca and the active form of vitamin D, $1,25(\text{OH})_2\text{D}_3$, stimulate the individual steps of transcellular Ca^{2+} transport by increasing the expression levels of the luminal Ca^{2+} channels, calbindins and the extrusion systems. The extracellular Ca^{2+} concentration is sensed by the calcium-sensing receptor (CaR) that might be involved in the intracellular signalling to regulate Ca^{2+} -responsive genes.

identify gene products in the kidney that are regulated by high dietary Ca and/or $1,25(\text{OH})_2\text{D}_3$, cDNA microarray analysis (15 000 cDNAs) was performed on kidney samples from $1,25(\text{OH})_2\text{D}_3$ - and high dietary Ca-treated $1\alpha\text{-OHase}$ knockout mice. In this study, $1,25(\text{OH})_2\text{D}_3$ induced a significant regulation of ~ 1000 genes, whereas dietary Ca supplementation of the $1\alpha\text{-OHase}$ knockout mice revealed ~ 2000 controlled genes as indicated in the Venn diagram (Figure 2) [13]. Interestingly, ~ 600 transcripts were regulated in both situations, suggesting the involvement in the dietary Ca-mediated rescue mechanism of these vitamin D-deficient mice (Figure 2; for overview data sheets, please see: <http://www.genomics.med.uu.nl/pub/bb/kidney/>). Conspicuous regulated genes encoded ion channels, channel-interacting proteins, kinases and other signalling molecules, and importantly Ca^{2+} -transporting proteins including the NCX1, calbindin- $\text{D}_{28\text{K}}$ and the Ca^{2+} sensor calmodulin. Dietary Ca supplementation in the $1\alpha\text{-OHase}$ knockout mice had a maximum effect on NCX1 expression, suggesting that this basolateral protein is an important extrusion mechanism in the process of transcellular Ca^{2+} reabsorption. Interestingly, several transcripts, previously not known to be involved in Ca^{2+} homeostasis, were significantly regulated. An intriguing question is how dietary Ca can regulate gene transcription. First, an increased dietary Ca load might increase the intracellular Ca^{2+} concentration in Ca^{2+} -transporting kidney cells. Previous studies already indicated Ca^{2+} -responsive elements in the promoter of calbindin- $\text{D}_{28\text{K}}$ and calmodulin [14]. Second, other reports point




Fig. 2. Venn diagram depicting the number of regulated genes in $1\alpha\text{-OHase}$ mice during dietary treatment. The number of genes regulated when comparing the three conditions $1\alpha\text{-OHase}$ knockout mice vs $1\alpha\text{-OHase}$ control mice (left), $1\alpha\text{-OHase}$ knockout mice vs $1\alpha\text{-OHase}$ knockout mice supplemented with dietary Ca (middle), and $1\alpha\text{-OHase}$ control mice vs Ca^{2+} -supplemented $1\alpha\text{-OHase}$ control mice (right). The number of total regulated genes on the DNA chip is depicted. Genes are shown in the overlapping regions that are regulated in two conditions.

to a role for the Ca^{2+} -sensing receptor in the kidney that senses the ambient Ca^{2+} concentration and transduces signals into the cell at the level of gene transcription (Figure 1) [15,16]. Functional analysis should reveal the regulatory pathways of the Ca^{2+} -sensitive proteins with respect to dietary Ca-mediated rescue of the disturbed Ca^{2+} balance in vitamin D-deficient animals. The emerging tools of genomics and proteomics are enabling the in-depth study of relationships between diet, genetics and function.

Is vitamin D indispensable?

Several studies supported the notion that vitamin D and Ca supplementation may prevent osteoporotic fractures in people known to be vitamin D deficient [17]. Osteoporosis, a systemic skeletal disease characterized by a low bone mass, is a major public health problem [18]. Nutritional deficiencies have a significant influence on the cause of osteoporosis. Previous studies indicated that a reduced supply of Ca^{2+} is associated with decreased bone mass and osteoporosis, whereas a chronic and severe vitamin D deficiency leads to osteomalacia, a metabolic bone disease characterized by a decreased mineralization of bone [18]. Results of various clinical trials suggested that Ca^{2+} supplementation may prevent vertebral fractures in the elderly. As outlined above, Ca supplementation in vitamin D-deficient mice models normalized the hypocalcaemia and restored the biomechanical properties of bone [3,4,8]. This treatment, however, does not appear as effective as $1,25(\text{OH})_2\text{D}_3$ replacement therapy, since bone growth remained impaired [8]. Hendy and co-workers demonstrated in $1\alpha\text{-OHase}$ and/or VDR knockout mice that optimal dietary Ca absorption requires $1,25(\text{OH})_2\text{D}_3/\text{VDR}$, whereas skeletal mineralization was dependent on adequate ambient Ca^{2+} and did not require the $1,25(\text{OH})_2\text{D}_3/\text{VDR}$ system [19]. Together, these studies indicate that Ca^{2+} cannot entirely substitute vitamin D in mineral and skeletal homeostasis, but the two agents have discrete and complementary functions.

In various clinical conditions associated with a disturbed Ca homeostasis, vitamin D analogues are administered. For instance, the treatment of choice for PDDR and for patients with chronic renal failure is long-term replacement therapy with $1,25(\text{OH})_2\text{D}_3$. Notably, the currently applied strategy of vitamin D and Ca^{2+} supplementation to patients with chronic renal failure has been associated with adverse effects, such as vascular calcification and calciphylaxis. It would be interesting to compare the effectiveness of Ca supplementation with the treatment with vitamin D analogues in these patient groups. Based on present evidence, chelated Ca^{2+} may be safely and effectively ingested by most people at doses generally recommended for treatment or prevention of Ca^{2+} -related disorders [20]. Further studies on potential dietary Ca-sensitive targets will provide insight into the molecular rescue mechanisms of dietary Ca supplementation.

Acknowledgements. This work was supported by grants from the Dutch Organization of Scientific Research (Zon-Mw 016.006.001) and the Dutch Kidney Foundation (C03.6017).

Conflict of interest statement. None declared.

References

- Jones G, Strugnelli SA, DeLuca HF. Current understanding of the molecular actions of vitamin D. *Physiol Rev* 1998; 78: 1193–1231
- Panda DK, Miao D, Tremblay ML *et al*. Targeted ablation of the 25-hydroxyvitamin D 1 α -hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. *Proc Natl Acad Sci USA* 2001; 98: 7498–7503
- Dardenne O, Prud'homme J, Arabian A, Glorieux FH, St-Arnaud R. Targeted inactivation of the 25-hydroxyvitamin D₃-1 α -hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin D-deficiency rickets. *Endocrinology* 2001; 142: 3135–3141
- Van Cromphaut SJ, Dewerchin M, Hoenderop JG *et al*. Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspects. *Proc Natl Acad Sci USA* 2001; 98: 13324–13329
- Takeyama K, Kitahara S, Sato T, Kobori M, Yanagisawa J, Kato S. 25-Hydroxyvitamin D₃ 1 α -hydroxylase and vitamin D synthesis. *Science* 1997; 277: 1827–1830
- Hoenderop JG, Dardenne O, Van Abel M *et al*. Modulation of renal Ca^{2+} transport protein genes by dietary Ca^{2+} and 1,25-dihydroxyvitamin D₃ in 25-hydroxyvitamin D₃-1 α -hydroxylase knockout mice. *FASEB J* 2002; 16: 1398–1406
- Dardenne O, Prud'homme J, Hacking SA, Glorieux FH, St-Arnaud R. Rescue of the pseudo-vitamin D deficiency rickets phenotype of CYP27B1-deficient mice by treatment with 1,25-dihydroxyvitamin D₃: biochemical, histomorphometric, and biomechanical analyses. *J Bone Miner Res* 2003; 18: 637–643
- Dardenne O, Prud'homme J, Hacking SA, Glorieux FH, St-Arnaud R. Correction of the abnormal mineral ion homeostasis with a high-calcium, high-phosphorus, high-lactose diet rescues the PDDR phenotype of mice deficient for the 25-hydroxyvitamin D-1 α -hydroxylase (CYP27B1). *Bone* 2003; 32: 332–340
- Goltzman D, Miao D, Panda DK, Hendy GN. Effects of calcium and of the vitamin D system on skeletal and calcium homeostasis: lessons from genetic models. *J Steroid Biochem Mol Biol* 2004; 89–90: 485–489
- Schlumbohm C, Harmeyer J. Dietary additions of lactose, casein and soy protein exerted only moderate effects on calcium homeostasis in calcitriol deficient piglets. *J Steroid Biochem Mol Biol* 2004; 89–90: 605–609
- Balsan S, Garabedian M, Larchet M *et al*. Long-term nocturnal calcium infusions can cure rickets and promote normal mineralization in hereditary resistance to 1,25-dihydroxyvitamin D. *J Clin Invest* 1986; 77: 1661–1667
- Hoenderop JG, Nilius B, Bindels RJ. Calcium absorption across epithelia. *Physiol Rev* 2005; 85: 373–422
- Hoenderop JG, Chon H, Gkika D *et al*. Regulation of gene expression by dietary Ca^{2+} in kidneys of 25-hydroxyvitamin D₃-1 α -hydroxylase knockout mice. *Kidney Int* 2004; 65: 531–539
- Arnold DB, Heintz N. A calcium responsive element that regulates expression of two calcium binding proteins in Purkinje cells. *Proc Natl Acad Sci USA* 1997; 94: 8842–8847
- Brown EM, MacLeod RJ. Extracellular calcium sensing and extracellular calcium signaling. *Physiol Rev* 2001; 81: 239–297
- Drueke TB. Modulation and action of the calcium-sensing receptor. *Nephrol Dial Transplant* 2004; 19 [Suppl 5]: V20–V26
- Larsen ER, Mosekilde L, Foldspang A. Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. *J Bone Miner Res* 2004; 19: 370–378
- Gennari C. Calcium and vitamin D nutrition and bone disease of the elderly. *Public Health Nutr* 2001; 4: 547–559
- Panda DK, Miao D, Bolivar I *et al*. Inactivation of the 25-hydroxyvitamin D 1 α -hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. *J Biol Chem* 2004; 279: 16754–16766
- Whiting SJ, Wood R, Kim K. Calcium supplementation. *J Am Acad Nurse Pract* 1997; 9: 187–192